Interleukin-37: A crucial cytokine with multiple roles in disease and potentially clinical therapy (Review)

  • Authors:
    • Lijuan Wang
    • Yanchun Quan
    • Yongfang Yue
    • Xueyuan Heng
    • Fengyuan Che
  • View Affiliations

  • Published online on: February 7, 2018     https://doi.org/10.3892/ol.2018.7982
  • Pages: 4711-4719
Metrics: HTML 0 views | PDF 0 views     Cited By (CrossRef): 0 citations

Abstract

Interleukin (IL)-37, a new IL-1 family member, has received increasing attention in recent years. In the past decade, it has been determined that IL‑37 is expressed in various normal cells and tissues and is regulated by inflammatory stimuli and pro‑cytokines via different signal transduction pathways. Recently, it has been found that IL‑37 is expressed in a variety of cancers, chronic inflammatory and autoimmune disorders, and exerts anti‑inflammatory effects. Moreover, a growing body of literature demonstrates that IL‑37 plays a vital role in inhibiting both innate and adaptive immune responses as well as inflammatory reactions. In addition, IL‑37 may prove to be a new and potentially useful target for effective cytokine therapy. Further evidence is needed to clarify in more detail the effects of IL‑37 in experimental and clinical studies. Based on an extensive summary of published data, the aim of this review is to outline the current knowledge of IL‑37, including the location, structure, expression, regulation and function, as well as the potential clinical applications of this cytokine.

References

1 

Moran EM and Mastaglia FL: Cytokines in immune-mediated inflammatory myopathies: Cellular sources, multiple actions and therapeutic implications. Clin Exp Immunol. 178:405–415. 2014. View Article : Google Scholar : PubMed/NCBI

2 

Hoeppli RE, Wu D, Cook L and Levings MK: The environment of regulatory T cell biology: Cytokines, metabolites and the microbiome. Front Immunol. 6:612015. View Article : Google Scholar : PubMed/NCBI

3 

Venkatesha SH, Dudics S, Acharya B and Moudgil KD: Cytokine-modulating strategies and newer cytokine targets for arthritis therapy. Int J Mol Sci. 16:887–906. 2014. View Article : Google Scholar : PubMed/NCBI

4 

Garlanda C, Dinarello CA and Mantovani A: The interleukin-1 family: Back to the future. Immunity. 39:1003–1018. 2013. View Article : Google Scholar : PubMed/NCBI

5 

Dinarello CA: Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood. 117:3720–3732. 2011. View Article : Google Scholar : PubMed/NCBI

6 

Smith DE: The biological paths of IL-1 family members IL-18 and IL-33. J Leukoc Biol. 89:383–392. 2011. View Article : Google Scholar : PubMed/NCBI

7 

Dinarello C, Arend W, Sims J, Smith D, Blumberg H, O'Neill L, Goldbach-Mansky R, Pizarro T, Hoffman H, Bufler P, et al: IL-1 family nomenclature. Nat Immunol. 11:9732010. View Article : Google Scholar : PubMed/NCBI

8 

Moretti S, Bozza S, Oikonomou V, Renga G, Casagrande A, Iannitti RG, Puccetti M, Garlanda C, Kim S, Li S, et al: IL-37 inhibits inflammasome activation and disease severity in murine aspergillosis. PLoS Pathog. 10:e10044622014. View Article : Google Scholar : PubMed/NCBI

9 

Boraschi D, Lucchesi D, Hainzl S, Leitner M, Maier E, Mangelberger D, Oostingh GJ, Pfaller T, Pixner C, Posselt G, et al: IL-37: A new anti-inflammatory cytokine of the IL-1 family. Eur Cytokine Netw. 22:127–147. 2011.PubMed/NCBI

10 

Taylor SL, Renshaw BR, Garka KE, Smith DE and Sims JE: Genomic organization of the interleukin-1 locus. Genomics. 79:726–733. 2002. View Article : Google Scholar : PubMed/NCBI

11 

Ye L and Huang Z: IL-37 restrains autoimmune diseases. Oncotarget. 6:21775–21776. 2015. View Article : Google Scholar : PubMed/NCBI

12 

Wang S, An W, Yao Y, Chen R, Zheng X, Yang W, Zhao Y, Hu X, Jiang E, Bie Y, et al: Interleukin 37 expression inhibits STAT3 to Suppress the proliferation and invasion of human cervical cancer cells. J Cancer. 6:962–969. 2015. View Article : Google Scholar : PubMed/NCBI

13 

Li Y, Wang Z, Yu T, Chen B, Zhang J, Huang K and Huang Z: Increased expression of IL-37 in patients with Graves' disease and its contribution to suppression of proinflammatory cytokines production in peripheral blood mononuclear cells. PLoS One. 9:e1071832014. View Article : Google Scholar : PubMed/NCBI

14 

Liu W, Deng L, Chen Y, Sun C, Wang J, Zhou L, Li H and Luo R: Anti-inflammatory effect of IL-37b in children with allergic rhinitis. Mediators Inflamm. 2014:7468462014. View Article : Google Scholar : PubMed/NCBI

15 

Murzin AG, Lesk AM and Chothia C: Beta-Trefoil fold. patterns of structure and sequence in the kunitz inhibitors interleukins-1 beta and 1 alpha and fibroblast growth factors. J Mol Biol. 223:531–543. 1992. View Article : Google Scholar : PubMed/NCBI

16 

Banchereau J, Pascual V and O'Garra A: From IL-2 to IL-37: The expanding spectrum of anti-inflammatory cytokines. Nat Immunol. 13:925–931. 2012. View Article : Google Scholar : PubMed/NCBI

17 

Nold MF, Nold-Petry CA, Zepp JA, Palmer BE, Bufler P and Dinarello CA: IL-37 is a fundamental inhibitor of innate immunity. Nat Immunol. 11:1014–1022. 2010. View Article : Google Scholar : PubMed/NCBI

18 

Busfield SJ, Comrack CA, Yu G, Chickering TW, Smutko JS, Zhou H, Leiby KR, Holmgren LM, Gearing DP and Pan Y: Identification and gene organization of three novel members of the IL-1 family on human chromosome 2. Genomics. 66:213–216. 2000. View Article : Google Scholar : PubMed/NCBI

19 

Smith DE, Renshaw BR, Ketchem RR, Kubin M, Garka KE and Sims JE: Four new members expand the interleukin-1 superfamily. J Biol Chem. 275:1169–1175. 2000. View Article : Google Scholar : PubMed/NCBI

20 

Ross R, Grimmel J, Goedicke S, Möbus AM, Bulau AM, Bufler P, Ali S and Martin MU: Analysis of nuclear localization of interleukin-1 family cytokines by flow cytometry. J Immunol Methods. 387:219–227. 2013. View Article : Google Scholar : PubMed/NCBI

21 

Akdis M, Burgler S, Crameri R, Eiwegger T, Fujita H, Gomez E, Klunker S, Meyer N, O'Mahony L, Palomares O, et al: Interleukins, from 1 to 37 and interferon-γ: Receptors, functions and roles in diseases. J Allergy Clin Immunol. 127:701–721. 2011. View Article : Google Scholar : PubMed/NCBI

22 

Imaeda H, Takahashi K, Fujimoto T, Kasumi E, Ban H, Bamba S, Sonoda H, Shimizu T, Fujiyama Y and Andoh A: Epithelial expression of interleukin-37b in inflammatory bowel disease. Clin Exp Immunol. 172:410–416. 2013. View Article : Google Scholar : PubMed/NCBI

23 

Pan G, Risser P, Mao W, Baldwin DT, Zhong AW, Filvaroff E, Yansura D, Lewis L, Eigenbrot C, Henzel WJ and Vandlen R: IL-1H, an interleukin 1-related protein that binds IL-18 receptor/IL-1Rrp. Cytokine. 13:1–7. 2001. View Article : Google Scholar : PubMed/NCBI

24 

Bufler P, Gamboni-Robertson F, Azam T, Kim SH and Dinarello CA: Interleukin-1 homologues IL-1F7b and IL-18 contain functional mRNA instability elements within the coding region responsive to lipopolysaccharide. Biochem J. 381:503–510. 2004. View Article : Google Scholar : PubMed/NCBI

25 

Kumar S, McDonnell PC, Lehr R, Tierney L, Tzimas MN, Griswold DE, Capper EA, Tal-Singer R, Wells GI, Doyle ML and Young PR: Identification and initial characterization of four novel members of the interleukin-1 family. J Biol Chem. 275:10308–10314. 2000. View Article : Google Scholar : PubMed/NCBI

26 

Dunn E, Sims JE, Nicklin MJ and O'Neill LA: Annotating genes with potential roles in the immune system: Six new members of the IL-1 family. Trends Immunol. 22:533–536. 2001. View Article : Google Scholar : PubMed/NCBI

27 

Bufler P, Azam T, Gamboni-Robertson F, Reznikov LL, Kumar S, Dinarello CA and Kim SH: A complex of the IL-1 homologue IL-1F7b and IL-18-binding protein reduces IL-18 activity. Proc Natl Acad Sci USA. 99:pp. 13723–13728. 2002; View Article : Google Scholar : PubMed/NCBI

28 

Li Y, Wang Y, Liu Y, Wang Y, Zuo X, Li Y and Lu X: The possible role of the novel cytokines il-35 and il-37 in inflammatory bowel disease. Mediators Inflamm. 2014:1363292014. View Article : Google Scholar : PubMed/NCBI

29 

Sharma S, Kulk N, Nold MF, Gräf R, Kim SH, Reinhardt D, Dinarello CA and Bufler P: The IL-1 family member 7b translocates to the nucleus and down-regulates proinflammatory cytokines. J Immunol. 180:5477–5482. 2008. View Article : Google Scholar : PubMed/NCBI

30 

He L, Liang Z, Zhao F, Peng L and Chen Z: Modulation of IL-37 expression by triptolide and triptonide in THP-1 cells. Cell Mol Immunol. 12:515–518. 2015. View Article : Google Scholar : PubMed/NCBI

31 

McNamee EN, Masterson JC, Jedlicka P, McManus M, Grenz A, Collins CB, Nold MF, Nold-Petry C, Bufler P, Dinarello CA and Rivera-Nieves J: Interleukin 37 expression protects mice from colitis. Proc Natl Acad Sci USA. 108:pp. 16711–16716. 2011; View Article : Google Scholar : PubMed/NCBI

32 

Su S, Duan J, Chen T, Huang X, Shang E, Yu L, Wei K, Zhu Y, Guo J, Guo S, et al: Frankincense and myrrh suppress inflammation via regulation of the metabolic profiling and the MAPK signaling pathway. Sci Rep. 5:136682015. View Article : Google Scholar : PubMed/NCBI

33 

Guo C, Xia Y, Niu P, Jiang L, Duan J, Yu Y, Zhou X, Li Y and Sun Z: Silica nanoparticles induce oxidative stress, inflammation and endothelial dysfunction in vitro via activation of the MAPK/Nrf2 pathway and nuclear factor-κB signaling. Int J Nanomedicine. 10:1463–1477. 2015. View Article : Google Scholar : PubMed/NCBI

34 

Fang HU, Zhang HH, Yang BX, Huang JL, Shun JL, Kong FJ, Peng-Xu, Chen ZG and Lu JM: Cdk5 contributes to inflammation-induced thermal hyperalgesia mediated by the p38 MAPK pathway in microglia. Brain Res. 1619:166–175. 2015. View Article : Google Scholar : PubMed/NCBI

35 

Lei YY, Wang WJ, Mei JH and Wang CL: Mitogen-activated protein kinase signal transduction in solid tumors. Asian Pac J Cancer Prev. 15:8539–8548. 2014. View Article : Google Scholar : PubMed/NCBI

36 

Grossi V, Peserico A, Tezil T and Simone C: p38α MAPK pathway: A key factor in colorectal cancer therapy and chemoresistance. World J Gastroenterol. 20:9744–9758. 2014. View Article : Google Scholar : PubMed/NCBI

37 

Jha SK, Jha NK, Kar R, Ambasta RK and Kumar P: p38 MAPK and PI3K/AKT signalling cascades inparkinson's disease. Int J Mol Cell Med. 4:67–86. 2015.PubMed/NCBI

38 

Lupia E, Pigozzi L, Goffi A, Hirsch E and Montrucchio G: Role of phosphoinositide 3-kinase in the pathogenesis of acute pancreatitis. World J Gastroenterol. 20:15190–15199. 2014. View Article : Google Scholar : PubMed/NCBI

39 

Yip PY: Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin (PI3K-Akt-mTOR) signaling pathway in non-small cell lung cancer. Transl Lung Cancer Res. 4:165–176. 2015.PubMed/NCBI

40 

Huang Z, Zhao GW, Gao CH, Chi XW, Zeng T, Hu YW, Zheng L and Wang Q: Mannose-capped lipoarabinomannan from mycobacterium tuberculosis induces Il-37 production via upregulating ERK1/2 and p38 in human type II alveolar epithelial cells. Int J Clin Exp Med. 8:7279–7287. 2015.PubMed/NCBI

41 

Rudloff I, Cho SX, Lao JC, Ngo D, McKenzie M, Nold-Petry CA and Nold MF: Monocytes and dendritic cells are the primary sources of interleukin 37 in human immune cells. J Leukoc Bio. 101:901–911. 2016. View Article : Google Scholar

42 

Gunaltay S, Ghiboub M, Hultgren O and Hörnquist EH: Reduced IL-37 production increases spontaneous chemokine expressions in colon epithelial cells. Dig Dis Sci. 62:1204–1215. 2017. View Article : Google Scholar : PubMed/NCBI

43 

Smithrithee R, Niyonsaba F, Kiatsurayanon C, Ushio H, Ikeda S, Okumura K and Ogawa H: Human β-defensin-3 increases the expression of interleukin-37 through CCR6 in human keratinocytes. J Dermatol Sci. 77:46–53. 2015. View Article : Google Scholar : PubMed/NCBI

44 

Yang Y, Zhang ZX, Lian D, Haig A, Bhattacharjee RN and Jevnikar AM: IL-37 inhibits IL-18-induced tubular epithelial cell expression of pro-inflammatory cytokines and renal ischemia-reperfusion injury. Kidney Int. 87:396–408. 2015. View Article : Google Scholar : PubMed/NCBI

45 

Xie Y, Li Y, Cai X, Wang X and Li J: Interleukin-37 suppresses ICAM-1 expression in parallel with NF-κB down-regulation following TLR2 activation of human coronary artery endothelial cells. Int immunopharmacolo. 38:26–30. 2016. View Article : Google Scholar

46 

Coll-Miró M, Francos-Quijorna I, Santos-Nogueira E, Torres-Espin A, Bufler P, Dinarello CA and López-Vales R: Beneficial effects of IL-37 after spinal cord injury in mice. Proc Natl Acad Sci USA. 113:pp. 1411–1416. 2016; View Article : Google Scholar : PubMed/NCBI

47 

Liu M, Guo S, Hibbert JM, Jain V, Singh N, Wilson NO and Stiles JK: CXCL10/IP-10 in infectious diseases pathogenesis and potential therapeutic implications. Cytokine Growth Factor Rev. 22:121–130. 2011.PubMed/NCBI

48 

Zhao M, Hu Y, Shou J, Su SB, Yang J and Yang T: IL-37 impairs host resistance to listeria infection by suppressing macrophage function. Biochem Biophys Res Commun. 485:563–568. 2017. View Article : Google Scholar : PubMed/NCBI

49 

Li S, Neff CP, Barber K, Hong J, Luo Y, Azam T, Palmer BE, Fujita M, Garlanda C, Mantovani A, et al: Extracellular forms of IL-37 inhibit innate inflammation in vitro and in vivo but require the IL-1 family decoy receptor IL-1R8. Proc Natl Acad Sci USA. 112:pp. 2497–2502. 2015; View Article : Google Scholar : PubMed/NCBI

50 

Zaccone P, Fehervari Z, Blanchard L, Nicoletti F, Edwards CK III and Cooke A: Autoimmune thyroid disease induced by thyroglobulin and lipopolysaccharide is inhibited by soluble TNF receptor type I. Eur J Immunol. 32:1021–1028. 2002. View Article : Google Scholar : PubMed/NCBI

51 

Dujmovic I, Mangano K, Pekmezovic T, Quattrocchi C, Mesaros S, Stojsavljevic N, Nicoletti F and Drulovic J: The analysis of IL-1 beta and its naturally occurring inhibitors in multiple sclerosis: The elevation of IL-1 receptor antagonist and IL-1 receptor type II after steroid therapy. J Neuroimmunol. 207:101–106. 2009. View Article : Google Scholar : PubMed/NCBI

52 

Nicoletti F, Patti F, DiMarco R, Zaccone P, Nicoletti A, Meroni P and Reggio A: Circulating serum levels of IL-1ra in patients with relapsing remitting multiple sclerosis are normal during remission phases but significantly increased either during exacerbations or in response to IFN-beta treatment. Cytokine. 8:395–400. 1996. View Article : Google Scholar : PubMed/NCBI

53 

Nicoletti F, Zaccone P, Di Marco R, Lunetta M, Magro G, Grasso S, Meroni P and Garotta G: Prevention of spontaneous autoimmune diabetes in diabetes-prone BB rats by prophylactic treatment with antirat interferon-gamma antibody. Endocrinology. 138:281–288. 1997. View Article : Google Scholar : PubMed/NCBI

54 

Nicoletti F, Di Marco R, Barcellini W, Magro G, Schorlemmer HU, Kurrle R, Lunetta M, Grasso S, Zaccone P and Meroni P: Protection from experimental autoimmune diabetes in the non-obese diabetic mouse with soluble interleukin-1 receptor. Eur J Immunol. 24:1843–1847. 1994. View Article : Google Scholar : PubMed/NCBI

55 

Akdis M, Aab A, Altunbulakli C, Azkur K, Costa RA, Crameri R, Duan S, Eiwegger T, Eljaszewicz A, Ferstl R, et al: Interleukins (from IL-1 to IL-38), interferons, transforming growth factor β and TNF-α: Receptors, functions and roles in diseases. J Allergy Clin Immunol. 138:984–1010. 2016. View Article : Google Scholar : PubMed/NCBI

56 

Højen JF, Rasmussen TA, Andersen KL, Winckelmann AA, Laursen RR, Gunst JD, Møller HJ, Fujita M, Østergaard L, Søgaard OS, et al: Interleukin-37 expression is increased in chronic HIV-1-Infected individuals and is associated with inflammation and the size of the total viral reservoir. Mol Med. 21:337–345. 2015. View Article : Google Scholar : PubMed/NCBI

57 

Wan ZY, Sun Z, Song F, Chen YF, Zhang WL, Wang HQ and Luo ZJ: Downregulated interleukin 37 expression associated with aggravation of intervertebral disc degeneration. Int J Clin Exp Pathol. 7:656–662. 2014.PubMed/NCBI

58 

Günaltay S, Nyhlin N, Kumawat AK, Tysk C, Bohr J, Hultgren O and Hultgren Hörnquist E: Differential expression of interleukin-1/Toll-like receptor signaling regulators in microscopic and ulcerative colitis. World J Gastroenterol. 20:12249–12259. 2014. View Article : Google Scholar : PubMed/NCBI

59 

Chen B, Huang K, Ye L, Li Y, Zhang J, Zhang J, Fan X, Liu X, Li L, Sun J, et al: Interleukin-37 is increased in ankylosing spondylitis patients and associated with disease activity. J Transl Med. 13:362015. View Article : Google Scholar : PubMed/NCBI

60 

Ye L, Ji L, Wen Z, Zhou Y, Hu D, Li Y, Yu T, Chen B, Zhang J, Ding L, et al: IL-37 inhibits the production of inflammatory cytokines in peripheral blood mononuclear cells of patients with systemic lupus erythematosus: Its correlation with disease activity. J Transl Med. 12:692014. View Article : Google Scholar : PubMed/NCBI

61 

Ji Q, Zeng Q, Huang Y, Shi Y, Lin Y, Lu Z, Meng K, Wu B, Yu K, Chai M, et al: Elevated plasma IL-37, IL-18 and IL-18BP concentrations in patients with acute coronary syndrome. Mediators Inflamm. 2014:1657422014. View Article : Google Scholar : PubMed/NCBI

62 

Wang X, Cai X, Chen L, Xu D and Li J: The evaluation of plasma and leukocytic IL-37 expression in early inflammation in patients with acute ST-segment elevation myocardial infarction after PCI. Mediators Inflamm. 2015:6269342015. View Article : Google Scholar : PubMed/NCBI

63 

Yu K, Min X, Lin Y, Huang Y, Huang S, Liu L, Peng Y, Meng K, Li D, Ji Q and Zeng Q: Increased IL-37 concentrations in patients with arterial calcification. Clin Chim Acta. 461:19–24. 2016. View Article : Google Scholar : PubMed/NCBI

64 

Zhao JJ, Pan QZ, Pan K, Weng DS, Wang QJ, Li JJ, Lv L, Wang DD, Zheng HX and Jiang SS: Interleukin-37 mediates the antitumor activity in hepatocellular carcinoma: Role for CD57+ NK cells. Sci Rep. 4:51772014. View Article : Google Scholar : PubMed/NCBI

65 

Ge G, Wang A, Yang J, Chen Y, Yang J, Li Y and Xue Y: Interleukin-37 suppresses tumor growth through inhibition of angiogenesis in non-small cell lung cancer. J Exp Clin Cancer Res. 35:132016. View Article : Google Scholar : PubMed/NCBI

66 

Wu BW, Zeng QT, Meng K and Ji QW: The potential role of IL-37 in atherosclerosis. Pharmazie. 68:857–860. 2013.PubMed/NCBI

67 

Sakai N, Van Sweringen HL, Belizaire RM, Quillin RC, Schuster R, Blanchard J, Burns JM, Tevar AD, Edwards MJ and Lentsch AB: Interleukin-37 reduces liver inflammatory injury via effects on hepatocytes and non-parenchymal cells. J Gastroenterol Hepatol. 27:1609–1616. 2012. View Article : Google Scholar : PubMed/NCBI

68 

Luo Y, Cai X, Liu S, Wang S, Nold-Petry CA, Nold MF, Bufler P, Norris D, Dinarello CA and Fujita M: Suppression of antigen-specific adaptive immunity by IL-37 via induction of tolerogenic dendritic cells. Proc Natl Acad Sci USA. 111:pp. 15178–15183. 2014; View Article : Google Scholar : PubMed/NCBI

69 

Jethwa H and Bowness P: The interleukin (IL)-23/IL-17 axis in ankylosing spondylitis: New advances and potentials for treatment. Clin Exp Immunol. 138:30–36. 2016. View Article : Google Scholar

70 

Ballak DB, van Diepen JA, Moschen AR, Jansen HJ, Hijmans A, Groenhof GJ, Leenders F, Bufler P, Boekschoten MV, Müller M, et al: IL-37 protects against obesity-induced inflammation and insulin resistance. Nat Commun. 5:47112014. View Article : Google Scholar : PubMed/NCBI

71 

Burdo TH, Lentz MR, Autissier P, Krishnan A, Halpern E, Letendre S, Rosenberg ES, Ellis RJ and Williams KC: Soluble CD163 made by monocyte/macrophages is a novel marker of HIV activity in early and chronic infection prior to and after anti-retroviral therapy. J Infect Dis. 204:154–163. 2011. View Article : Google Scholar : PubMed/NCBI

72 

Sandler NG, Wand H, Roque A, Law M, Nason MC, Nixon DE, Pedersen C, Ruxrungtham K, Lewin SR, Emery S, et al: Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis. 203:780–790. 2011. View Article : Google Scholar : PubMed/NCBI

73 

Wu GC, Li HM, Wang JB, Leng RX, Wang DG and Ye DQ: Elevated plasma interleukin-37 levels in systemic lupus erythematosus patients. Lupus. 25:1377–1380. 2016. View Article : Google Scholar : PubMed/NCBI

74 

Song L, Qiu F, Fan Y, Ding F, Liu H, Shu Q, Liu W and Li X: Glucocorticoid regulates interleukin-37 in systemic lupus erythematosus. J Clin Immunol. 33:111–117. 2013. View Article : Google Scholar : PubMed/NCBI

75 

Yang T, Fang F, Chen Y, Ma J, Xiao Z, Zou S, Zheng N, Yan D, Liao S, Chen S, et al: Elevated plasma interleukin-37 playing an important role in acute coronary syndrome through suppression of ROCK activation. Oncotarget. 8:9686–9695. 2017.PubMed/NCBI

76 

Liu K, Tang Q, Zhu X and Yang X: IL-37 increased in patients with acute coronary syndrome and associated with a worse clinical outcome after ST-segment elevation acute myocardial infarction. Clin Chim Acta. 468:140–144. 2017. View Article : Google Scholar : PubMed/NCBI

77 

Xu D, Wang A, Jiang F, Hu J and Zhang X: Effects of interleukin-37 on cardiac function after myocardial infarction in mice. Int J Clin Exp Pathol. 8:5247–5251. 2015.PubMed/NCBI

78 

Zhang XQ, Tang R, Li L, Szucsik A, Javan H, Saegusa N, Spitzer KW and Selzman CH: Cardiomyocyte-specific p65 NF-kappaB deletion protects the injured heart by preservation of calcium handling. Am J Physiol Heart Circ Physiol. 305:H1089–H1097. 2013. View Article : Google Scholar : PubMed/NCBI

79 

Zeng M, Wei X, Wu Z, Li W, Li B, Zhen Y, Chen J, Wang P and Fei Y: NF-κB-mediated induction of autophagy in cardiac ischemia/reperfusion injury. Biochem Biophys Res Commun. 436:180–185. 2013. View Article : Google Scholar : PubMed/NCBI

80 

Li J, Zhai Y, Ao L, Hui H, Fullerton DA, Dinarello CA and Meng X: Interleukin-37 suppresses the inflammatory response to protect cardiac function in old endotoxemic mice. Cytokine. 95:55–63. 2017. View Article : Google Scholar : PubMed/NCBI

81 

Ding VA, Zhu Z, Xiao H, Wakefield MR, Bai Q and Fang Y: The role of IL-37 in cancer. Med Oncol. 33:682016. View Article : Google Scholar : PubMed/NCBI

82 

Abulkhir A, Samarani S, Amre D, Duval M, Haddad E, Sinnett D, Leclerc JM, Diorio C and Ahmad A: A protective role of IL-37 in cancer: A new hope for cancer patients. J Leukoc Biol. 101:395–406. 2017. View Article : Google Scholar : PubMed/NCBI

83 

Moretta L, Pietra G, Montaldo E, Vacca P, Pende D, Falco M, Del Zotto G, Locatelli F, Moretta A and Mingari MC: Human NK cells: From surface receptors to the therapy of leukemias and solid tumors. Front Immunol. 5:872014. View Article : Google Scholar : PubMed/NCBI

84 

Kunz M and Ibrahim SM: Cytokines and cytokine profiles in human autoimmune diseases and animal models of autoimmunity. Mediators Inflamm. 2009:9792582009. View Article : Google Scholar : PubMed/NCBI

85 

Semerano L, Assier E and Boissier MC: Anti-cytokine vaccination: A new biotherapy of autoimmunity? Autoimmun Rev. 11:785–786. 2012. View Article : Google Scholar : PubMed/NCBI

86 

Taylor PC and Williams RO: Combination cytokine blockade: The way forward in therapy for rheumatoid arthritis? Arthritis Rheumatol. 67:14–16. 2015. View Article : Google Scholar : PubMed/NCBI

87 

Striz I, Brabcova E, Kolesar L and Sekerkova A: Cytokine networking of innate immunity cells: A potential target of therapy. Clin Sci (Lond). 126:593–612. 2014. View Article : Google Scholar : PubMed/NCBI

88 

Gao W, Kumar S, Lotze MT, Hanning C, Robbins PD and Gambotto A: Innate immunity mediated by the cytokine IL-1 homologue 4 (IL-1H4/IL-1F7) induces IL-12-dependent adaptive and profound antitumor immunity. J Immunol. 170:107–113. 2003. View Article : Google Scholar : PubMed/NCBI

89 

Yin D, Naji DH, Xia Y, Li S, Bai Y, Jiang G, Zhao Y, Wang X, Huang Y, Chen S, et al: Genomic Variant in IL-37 confers a significant risk of coronary artery disease. Scientific reports. 7:421752017. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

April 2018
Volume 15 Issue 4

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Wang, L., Quan, Y., Yue, Y., Heng, X., & Che, F. (2018). Interleukin-37: A crucial cytokine with multiple roles in disease and potentially clinical therapy (Review). Oncology Letters, 15, 4711-4719. https://doi.org/10.3892/ol.2018.7982
MLA
Wang, L., Quan, Y., Yue, Y., Heng, X., Che, F."Interleukin-37: A crucial cytokine with multiple roles in disease and potentially clinical therapy (Review)". Oncology Letters 15.4 (2018): 4711-4719.
Chicago
Wang, L., Quan, Y., Yue, Y., Heng, X., Che, F."Interleukin-37: A crucial cytokine with multiple roles in disease and potentially clinical therapy (Review)". Oncology Letters 15, no. 4 (2018): 4711-4719. https://doi.org/10.3892/ol.2018.7982